|
Cardiovascular disease is the biggest cause of mortality among people with type 1 and type 2 diabetes, with chronic hyperglycaemia causing vascular damage, while in type 2 diabetes other risk factors may also present in the prediabetes phase. This episode discusses the importance of optimising control of cardiovascular risk factors such as blood pressure, lipids and smoking status, with Prof. Naveed Sattar, Professor of Metabolic Medicine at the University of Glasgow.
Do you have a question for our expert faculty? This series will feature episodes aiming to address areas with unanswered clinical questions; first up we will be speaking to Prof. Stephen Bain about offering cardioprotective agents in type 2 diabetes. Send any questions to contact@knowledgeinpractice.eu or message us on Twitter/LinkedIn.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
References:
Disclosures:
Professor Naveed Sattar declares the following:
Advisory board: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi
Speaker honoraria: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi
Institutional research grant: Boehringer Ingelheim
Funding statement:
This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education. |